Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Accumulated Expenses data on record, last reported at $35.6 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 23.16% year-over-year to $35.6 million; the TTM value through Dec 2025 reached $35.6 million, up 23.16%, while the annual FY2025 figure was $35.6 million, 23.16% up from the prior year.
  • Accumulated Expenses reached $35.6 million in Q4 2025 per CRNX's latest filing, up from $32.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $35.6 million in Q4 2025 and bottomed at $3.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $14.3 million, with a median of $11.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: surged 137.03% in 2024, then grew 6.97% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $6.6 million in 2021, then skyrocketed by 37.84% to $9.1 million in 2022, then skyrocketed by 59.86% to $14.5 million in 2023, then skyrocketed by 98.99% to $28.9 million in 2024, then rose by 23.16% to $35.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $35.6 million in Q4 2025, $32.4 million in Q3 2025, and $21.8 million in Q2 2025.